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Abstract 
 
Introduction: The causes of pain in early/moderate Parkinson’s disease (PD) are 
not well understood. Although peripheral factors such as rigidity, reduced joint 
movements and poor posture may contribute towards the development of pain, 
central mechanisms including altered nociceptive processing may also be involved. 
Methods: We performed a large clinical study to investigate potential factors 
contributing towards pain in early/moderate PD. We recruited 1957 PD participants 
who had detailed assessments of pain, motor and non-motor symptoms. The King’s 
Parkinson’s Pain scale was used to quantify different subtypes of pain. 
Results: 85% of participants reported pain (42% with moderate to severe pain). Pain 
influenced quality of life more than motor symptoms in a multiple regression model. 
Factors predicting overall pain severity included affective symptoms, autonomic 
symptoms, motor complications, female gender and younger age, but not motor 
impairment or disease duration. There was negligible correlation between the 
severity of motor impairment and the severity of musculoskeletal or dystonic pain as 
well as between the severity of OFF period motor problems and the severity of OFF 
period pain or OFF period dystonic pain. Features of central sensitization, including 
allodynia and altered pain sensation were common in this population. The use of 
drugs targeting central pain was very low. 
Conclusions: Pain in early/moderate PD cannot be explained by peripheral factors. 
Central causes may play a much more important role than previously considered. 
These results should lead to a major shift in the investigation and management of 
this common and disabling symptom.
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Introduction  
 
Chronic pain affects 60-80% of Parkinson’s disease (PD) patients and is often a 
disabling symptom [1–3]. In the widely used Ford classification, the most common 
subtypes of PD pain are musculoskeletal, radicular and dystonic [4]. Central pain is 
thought to be fairly uncommon in PD [1,2,4]. Pain in PD may be a direct 
consequence of other disease-related symptoms: mobility problems, including 
stiffness, reduced joint movements and poor posture are felt to be the main cause of 
musculoskeletal pain and radicular pain; OFF-period mobility problems and dystonic 
contractions are thought to be the main cause of OFF-period pain [4,5].  
 
While chronic pain can be caused by peripheral tissue damage, an alternative 
mechanism is dysfunction of pain regulatory systems within the brain, leading to 
amplification of the pain signal (central sensitization). It is increasingly recognised 
that many if not most cases of chronic pain are due to altered nociceptive processing 
within the central nervous system [6,7].  
 
There are several potential mechanisms that may lead to enhanced central 
processing of pain signals in PD. The dopaminergic pathway from the ventral 
tegmental area to the nucleus accumbens is an important anti-nociceptive pathway, 
which degenerates in PD [8]. Furthermore brainstem serotonergic and 
norepinephrinergic neurons degenerate prior to the onset of motor symptoms in PD 
[9,10]. Degeneration of these neurons is proposed to be a cause of affective and 
autonomic symptoms in PD [10]. However these neurons are also the source of 
powerful ascending and descending anti-nociceptive pathways and their 
degeneration would therefore be predicted to cause central sensitization of pain 
signals [11]. Indeed many analgesic drugs, including duloxetine and amitriptyline act 
through enhancing transmission in these pathways [12]. Reduced pain thresholds 
[13], altered pain evoked electrical responses [14] and increased pain evoked cortical 
network activation [15,16], all provide evidence that altered central processing of pain 
may be an important contributing factor towards pain in PD.  
 
We had several objectives in this study:- 
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1) We hypothesised that pain is an important symptom leading to impaired quality of 
life in PD. We compared the contribution of pain and motor symptoms in determining 
quality of life in a large population of participants with relatively early stage PD. 
 
2) We hypothesised that a large detailed clinical study would help us to understand 
the causes as well as the potential treatments of pain in PD. We used the King’s 
Parkinson's Pain scale to classify and quantify PD pain into different subtypes [17]. 
We investigated whether the severity of other disease-related symptoms correlated 
with the severity of the pain subtypes felt to be caused by these symptoms, including 
whether or not the severity of mobility problems correlated with the severity of 
musculoskeletal and radicular pain. We also investigated for symptoms suggesting 
centrally-generated pain including cutaneous allodynia. 
 
3) We hypothesised that pain frequency and severity in PD would correlate with the 
severity of other symptoms attributable to serotonergic and norepinephrinergic 
depletion, including anxiety, depression and autonomic dysfunction. 
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Methods 
Ethical Approval 
 
The study was carried out in accordance with the Declaration of Helsinki and 
authorized by a UK ethics committee (National Research Ethics Service Committee 
North West – Preston). All patients gave written consent prior to any study 
procedures. 
Participants 
 
Participants were recruited from 68 centres throughout the UK. All participants were 
recruited from one of two large UK multi-centre longitudinal epidemiological and 
biomarker studies in PD, those being the Tracking Parkinson’s study [18] and the 
Oxford Monument Discovery Study [19].  The inclusion and exclusion criteria for 
these other studies have been previously published [18,19]. The pain study was a 
sub-study of these other studies using the same research nurses, although it was 
funded and run separately. It was performed at a single occasion at any one of the 
main study visits. 
Pain assessments 
 
Pain was assessed using the Short Form McGill Pain Questionnaire (SFMPQ) [20], 
Visual Analogue Scale (VAS) for pain severity over the last month and the recently 
validated Kings Parkinson’s Pain Scale (KPPS) [17]. Participants scoring >0 on the 
SFMPQ were defined as having pain.  Similar to previous large pain studies, 
participants scoring 5 or more on the VAS for pain severity over the last month were 
defined as having moderate to severe pain [21]. For those with more than 1 type of 
pain, the most troublesome pain was used to record the SFMPQ and VAS ratings. 
 
The King’s Parkinson’s Pain Scale quantifies pain across different subtypes. For 
each subtype the participant rates severity (0-3) and frequency (0-4). The frequency 
and severity are multiplied together to create a total score for that subtype of pain. 
The subtypes include musculoskeletal pain (pain around the joints), radicular pain 
(shooting pain down the limbs), dystonic pain (OFF period pain in a region of 
dystonia), generalised OFF period pain, lower abdominal pain, visceral pain (pain 
related to an internal organ such as liver, stomach or bowels), restless leg syndrome 
(RLS) and central pain (a generalised constant dull aching pain).  
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Other Assessments 
 
Detailed analysis of motor and non-motor symptoms using validated scales was 
performed to document whether or not the severity of different pain types could be 
explained by the severity of other motor and non-motor symptoms. The analysis 
included the Movement Disorder Society Unified Parkinson’s Disease Rating Scale 
(MDS-UPDRS) Part III to document the motor impairment severity, MDS-UPDRS 
Part IV to document the severity of motor fluctuations, the Leeds Anxiety and 
Depression Scale (LADS) anxiety score (LADS-A) and depression score (LADS-D) 
[22] the Scales for Outcomes in Parkinson’s disease – Autonomic Symptoms 
(SCOPA-AUT) to document the severity of autonomic symptoms, the Montreal 
Cognitive Assessment (MoCA) and the EQ-5D index, a measure of quality of life 
(QoL).  
 
The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scale was 
used to document the presence of neuropathic pain [23]. The LANSS scale is 
validated to detect neuropathic pain and uses an assessment of sensory function 
(cutaneous allodynia and altered pinprick threshold over the painful area) as well as 
pain descriptors to classify pain which is likely to be centrally generated. Participants 
were asked whether the pain was better in the ON state, the OFF state or no 
different. They were also asked which if any of their ‘non Parkinson’s medications’ 
improved pain. However we did not collect detailed information regarding which pain 
medications were being taken at the time of assessment. 
 
All scales were performed in at least 1600 of the participants with the exception of 
the SCOPA-AUT, which was not part of the Oxford Monument Discovery study 
therefore was only performed in 816 participants. All scales were performed within 6 
months of each other. Thus the motor and non-motor assessments (MDS-UPDRS, 
LADS, EQ-5D, SCOPA and MoCA) were all done at the same time. The pain 
assessments (SFMPQ, VAS, LANSS and KPPS) were all done at the same time. In 
917 participants the pain assessments were done at the same time as the motor and 
non-motor assessments. In 527 the pain assessments were done within 6 months 
after the motor and non-motor assessments. In 513 participants, the pain 
assessments were done within 6 months before the motor and non-motor 
assessments. All scales and assessments were performed in the ON state. In the 
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Tracking Parkinson’s and Oxford Discovery studies, all participants had the MDS-
UPDRS III performed in the OFF state (after 12 hours withdrawal of anti-parkinsonian 
medication) at a single visit. However in many cases the pain assessments were 
done more than 6 months from the MDS-UPDRS-III OFF so we included MDS-
UPDRS-III OFF data only in the 491 participants in whom MDS-UPDRS-III OFF was 
done within 6 months of the pain assessments. 
 
Statistical Analysis 
 
Statistical analysis was performed using SPSS (version 22, IBM). Multiple linear 
regression analysis was used to investigate factors predicting quality of life (EQ-5D 
index) in PD. Predictor variables in the model included severity of pain (SFMPQ), 
severity of motor impairment (MDS-UPDRS-III) and severity of motor complications 
(MDS-UPDRS-IV). 
 
Multiple linear regression analysis was used to investigate factors predicting the 
overall severity of pain (SFMPQ) in PD. Candidate variables in the model were MDS-
UPDRS-III, MDS-UPDRS-IV, SCOPA-AUT, LADS, MoCA, age, disease duration and 
female gender.  
 
Correlation analysis was used to investigate the relationship between different types 
of pain (as measured with the Kings Parkinson’s Pain Scale) and other disease 
related factors. Due to the non-parametric nature of the individual scales, in particular 
those in the King’s Parkinson’s Pain Scale, non-parametric (Spearman’s rank) 
correlation analysis was used.  
. 
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Results 
Study population and pain characteristics  
 
1957 participants were recruited into the UK Parkinson's Pain Study. 65% were male. 
Table 1 shows the characteristics of the study population. This was a population with 
relatively early PD. 1648 out of 1944 participants recording SFMPQ (85%) reported 
pain at the time of assessment. 808 participants (42%) reported moderate to severe 
pain. The main pain subtypes were: musculoskeletal pain (66% of those with pain), 
radicular pain (34%), dystonic pain (16%), generalised OFF pain (9%), dyskinetic 
pain (10%), lower abdominal pain (16%), visceral pain (16%), central pain (27%) and 
restless leg syndrome (23%). 395 participants reported 1 type of pain, 389 reported 2 
types, 281 reported 3 types and the rest reported 4 or more types of pain. 
  
Effects of pain and motor symptoms on quality of life  
 
Predictors of quality of life (EQ-5D index) in the regression model (Table 2) were 
motor examination (MDS-UPDRS III), motor complications (MDS-UPDRS IV) and 
pain (SFMPQ). The model accounted for 26% of the variance in quality of life. In this 
population of participants with fairly early PD, all of the variables had an effect on 
quality of life and the effect of pain was higher than that of motor disability or motor 
fluctuations. 
 
Central mechanisms and pain 
 
33% of those with pain had evidence for altered sensory processing over the painful 
area, this being either cutaneous allodynia, altered pinprick threshold or both. 10% of 
participants with pain had a LANSS score of ≥12 indicating the presence of 
neuropathic pain [23].  
Factors predicting pain in PD  
 
Table 3 shows the results of a regression analysis using the overall severity of pain 
(SFMPQ) as the outcome variable and the severity of other disease related 
symptoms as predictor variables. The model explained 21% of the overall variance in 
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pain severity. Factors having a statistically significant effect on pain severity were 
motor complications, autonomic symptoms, affective symptoms, younger age and 
female gender. The severity of motor impairment and the severity of cognitive 
impairment did not have a statistically significant effect on the severity of pain.  
 
Medications and pain in PD 
 
Pain was reported to be worse in the OFF state by 17% of participants, whereas 2% 
felt it was worse in the ON state and 81% felt there was no difference between the 
ON and OFF state with regards to pain severity. Regarding medications which were 
being used to treat pain and which were felt by the participant to be effective for PD 
pain, 28% of those with pain reported benefit from paracetamol (acetaminophen), 
compared to 12% from non steroidal anti-inflammatory drugs (NSAIDS) and 10% 
from using opioids. Only 3% of participants with pain derived benefit from drugs 
targeting central pain mechanisms, including gabapentin, pregabalin, duloxetine and 
amitriptyline. 
 
Correlation between individual subtypes of pain and other disease related 
symptoms  
 
Table 4 shows the correlation between different types of pain (as measured with the 
King’s Parkinson’s pain scale) and other disease-related symptoms. There was 
negligible correlation between the severity of musculoskeletal pain and the severity 
of motor symptoms (MDS-UPDRS III) in both the ON and OFF states. There was 
weak correlation between the severity of musculoskeletal pain and the severity of 
motor complications (MDS-UPDRS-IV), autonomic symptoms (SCOPA-AUT), anxiety 
(LADS-A) and depression (LADS-D).   
 
Similarly there was negligible correlation between radicular pain severity and the 
severity of motor symptoms. There was only weak correlation with the severity of 
motor complications, autonomic symptoms, anxiety and depression.  
 
There was poor correlation between the severity of OFF period motor problems as 
measured with MDS-UPDRS-III OFF and the severity of either dystonic OFF pain or 
generalised OFF pain. OFF period pain was significantly correlated with MDS-
UPDRS-IV but the correlation was only weak. Dyskinetic pain correlated with the 
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severity of motor fluctuations, although only with a very weak association. Both lower 
abdominal pain and visceral pain correlated with constipation scores (Q1.11 in MDS-
UPDRS). However the association was only weak. Both of these types of pain 
correlated with autonomic symptoms, again only with a weak association. 
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Discussion  
 
Influence of pain on quality of life in PD 
 
Our first hypothesis was that pain is an important symptom leading to impaired 
quality of life in PD. In our study, pain was extremely common in this large population 
of participants at a relatively early stage of PD. 85% of participants reported pain and 
42% of participants reported moderate to severe pain. Although we did not have a 
control group, the frequency of pain is clearly much higher than previously reported 
in the general population. A European study of 46,394 participants, using similar 
inclusion criteria and definitions of pain severity to our study, noted a prevalence of 
moderate to severe pain of 19%, although the figure was 13% if only the 3800 UK 
participants were included [21]. Our results therefore confirm previous studies 
indicating a very high prevalence of pain in PD [1,2].  
 
In our study pain had an effect on quality of life, which was greater than motor 
impairment and comparable to the effect of motor complications.  Other smaller 
studies have reported similar findings [24]. Given the amount of research that has 
gone into understanding mobility problems in PD, it is clear that there needs to be 
more research into understanding the causes of pain in PD with a view to developing 
improved treatments.  
 
It should be highlighted that participants in our study had fairly mild motor 
impairment/complications and results may be different in a more severely-affected 
population. 
 
Relationship between pain and other disease symptoms 
 
Our second hypothesis was that a large and detailed clinical study would help us to 
understand the causes and therefore identify potential treatments for pain in PD. The 
severity of motor impairment did not predict the overall severity of pain (SFMPQ). 
Furthermore the severity of motor fluctuations only weakly predicted variance in the 
severity of pain. Thus mobility issues are probably not a very important cause for the 
markedly increased frequency and severity of pain in PD.  
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The size and scope of our study enabled us for the first time, to perform an analysis 
of the factors which may be contributing towards different subtypes of pain in PD. 
Musculoskeletal pain and radicular pain are the most common types of pain in PD. 
We saw negligible correlation between these pain subtypes and MDS-UPDRS-III, 
suggesting that mobility factors are not an important cause. Off period dystonic pain 
is common in PD and is understandably attributed to painful dystonic muscle 
contractions despite the fact that with one or two exceptions, dystonia is usually not a 
painful condition. It is very interesting therefore that there was negligible correlation 
between the severity of dystonic pain and the severity of the MDS-UPDRS-III OFF 
motor scores. Similarly there was negligible correlation between generalised OFF 
period pain and MDS-UPDRS-OFF scores. Dyskinetic pain was only weakly 
correlated with motor fluctuation scores (MDS-UPDRS-IV). Abdominal pain and 
visceral pain correlated with constipation severity but with only a small effect size. 
 
Our results suggest that peripheral factors are not an important cause of these 
different subtypes of pain in PD. Although we attempted to analyse peripheral factors 
in detail, we cannot exclude the possibility that others which could have contributed 
to pain were not adequately assessed in our study. However the high prevalence of 
either cutaneous allodynia or altered pinprick threshold over the painful area 
suggests that central mechanisms may be a more important contributing factor 
towards pain than previously considered. Indeed the LANSS scale classified 10% of 
participants as having centrally-generated neuropathic pain. It is well recognised that 
there is a very poor correlation between the severity of osteoarthritic problems on 
imaging and pain severity [25]. In PD patients with what is described to be 
musculoskeletal shoulder problems, there is enhanced sensory processing over the 
painful shoulder implicating a role for central factors in contributing towards 
musculoskeletal pain in PD [26].  
 
Despite the lack of detailed data on analgesic use, it is noteworthy that only a very 
small proportion of participants were using drugs which target central mechanisms. 
Our results suggest that more widespread use of these medications should be 
considered as a treatment for pain in PD.  
 
Our study data confirms previous reports that female sex is a contributing factor 
towards pain in PD [1]. Interestingly, age was inversely associated with pain severity.  
The relationship between pain and age is complex, although similar findings have 
previously been reported in the general population [27]. Pain due to PD has been 
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linked to younger age and age at onset [2]. Pain was not associated with disease 
duration in our study, although the predominance of fairly early PD participants in our 
study precludes too much importance being given to this finding. 
 
We acknowledge study limitations which could have affected these correlations. The 
population was of early/moderate PD and results may be different in more severely-
affected participants. There was a delay of up to 6 months between pain and motor 
assessments which could have affected correlations. We did not assess in detail the 
potential confounding effects of analgesic use. 
 
 
Relationship between pain and symptoms of brainstem monoamine 
dysfunction 
 
Our third hypothesis was that pain frequency and severity in PD would correlate with 
the severity of other symptoms attributable to serotonergic and norepinephrinergic 
depletion. Consistent with this, the severity of autonomic symptoms, anxiety and 
depression predicted the severity of pain. A recent study showed no association 
between pain severity and the severity of small fibre neuropathy in PD [28], 
suggesting that central factors may be more important. Although our data do not 
enable us to establish a definite cause or direction of this association, we propose 
that a shared pathophysiology of degeneration in brainstem monoamine pathways 
from premotor stages of PD (Braak stage 2) onwards, contributes to causing 
autonomic symptoms, affective symptoms and altered processing of pain in PD.  
 
The results of this study suggest that a major shift in the way we approach this 
common and disabling symptom in PD is required. In one small open study, central 
pain in PD was reduced by duloxetine [29], and further studies with this type of 
medication are clearly warranted, and should assess effects on the various pain 
subtypes. Similarly, deep brain stimulation improved pain in PD, separate from the 
improvement in mobility symptoms [30], again stressing the role of central 
mechanisms, distinct from those driving motor impairment.  
 
Limitations of the study 
 
We acknowledge that there are several limitations to our study which mean that the 
results must be interpreted cautiously. The study population was mainly of early and 
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moderate cases and detailed data on other comorbidities and analgesic use were not 
available, so the results are not necessarily generalisable to all patients with PD. The 
LANNS scale while not specifically validated in PD is rated as ‘suggested’ by experts 
in PD related pain [31]. Although participants were assessed ON medication, we did 
not standardise the timing of assessments with regards to ON/OFF state and in 
some cases the pain assessments were not performed at the same time as other 
study measures. As with any large study there is some missing data which could 
have affected the results. 
 
We acknowledge that it is possible our results are caused in part by the type of 
patients enrolled and the limitations of our methodology. Other similar studies with 
different populations and methodologies will help to clarify this point. 
 
Conclusions 
 
The UK Parkinson's Pain Study is the largest and most detailed study of pain in PD 
ever performed. Detailed phenotyping and high power from a large number of 
participants allowed us for the first time to explore in detail the factors contributing to 
subtypes of pain in PD. In our study population, we found that peripheral factors are 
not an important cause of pain in PD, and conclude that central factors are more 
important than previously considered.  
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Table Legends 
 
Table 1: Characteristics of the study population 
SD, standard deviation; LADS-Anxiety, Leeds Anxiety and Depression Scale-Anxiety; 
LADS-Depression, Leeds Anxiety and Depression Scale-Depression; MDS-UPDRS-
III, Unified Parkinson’s disease Rating Scale Part III (motor examination); MDS-
UPDRS-IV, Unified Parkinson’s disease Rating Scale Part IV (motor complications); 
SCOPA-AUT, the Scales for Outcomes in Parkinson’s disease – Autonomic 
Symptoms. MoCA, Montreal Cognitive Assessment; SFMPQ, Short Form McGill Pain 
Questionnaire; EQ-5D Index, Quality of Life Scale. 
 
Table 2: Multiple linear regression for health-related Quality of life (EQ-5D 
Index) 
MDS-UPDRS-III, Unified Parkinson’s disease Rating Scale Part III (motor 
examination); MDS-UPDRS-IV, Unified Parkinson’s disease Rating Scale Part IV 
(motor complications); SFMPQ, Short Form McGill Pain Questionnaire.  
 
 
Table 3: Multiple linear regression for pain severity - Short form McGill Pain 
Questionnaire (SFMPQ) 
MDS-UPDRS-III, Unified Parkinson’s disease Rating Scale Part III (motor 
examination); MDS-UPDRS-IV, Unified Parkinson’s disease Rating Scale Part IV 
(motor complications); SCOPA-AUT, the Scales for Outcomes in Parkinson’s disease 
– Autonomic Symptoms; LADS, Leeds Anxiety and Depression Scale; MoCA, 
Montreal Cognitive Assessment.  
 
Table 4: Correlation between the severity of individual subtypes of pain and 
other disease related symptoms. 
Spearman’s rank correlation coefficient (rho); * P<0.05; ** P<0.001 
Individual pain subtypes were quantified using the King’s Parkinson’s Pain Scale. 
 
MDS-UPDRS-III, Unified Parkinson’s disease Rating Scale Part III (motor 
examination); MDS-UPDRS-III (OFF), UPDRS-III after 12 hours medication 
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withdrawal; MDS-UPDRS-IV, Unified Parkinson’s disease Rating Scale Part IV 
(motor complications); SCOPA-AUT, the Scales for Outcomes in Parkinson’s disease 
– Autonomic Symptoms; LADS-A, Leeds Anxiety and Depression Scale-Anxiety; 
LADS-D, Leeds Anxiety and Depression Scale-Depression; Constipation, UPDRS 
1.11. 
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Table 1: Characteristics of the study population 
 
     Mean   SD  n  
 
Age (Year)    68   9.5  1914   
Disease Duration (Years)  3.0   2.1  1887 
LADS-Anxiety   4.1   3.6  1737 
LADS-Depression   4.5   3.2  1729 
MDS-UPDRS-III   27   13.6  1657 
MDS-UPDRS-III (OFF)  33.5   15.5  495 
MDS-UPDRS-IV   1.2   2.4  1685 
SCOPA-AUT    12.5   7.2  823 
MoCA     25.1   3.6  1706 
SFMPQ    6.8   6.6  1944 
EQ-5D Index    0.71   0.24  1751 
_______________________________________________________________ 
 
 
SD, standard deviation; LADS-Anxiety, Leeds Anxiety and Depression Scale-Anxiety; LADS-Depression, Leeds Anxiety and 
Depression Scale-Depression; MDS-UPDRS-III, Unified Parkinson’s disease Rating Scale Part III (motor examination); MDS-
UPDRS-IV, Unified Parkinson’s disease Rating Scale Part IV (motor complications); SCOPA-AUT, the Scales for Outcomes in 
Parkinson’s disease – Autonomic Symptoms. MoCA, Montreal Cognitive Assessment; SFMPQ, Short Form McGill Pain 
Questionnaire; EQ-5D Index, Quality of Life Scale. 
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Table 2: Multiple linear regression for health-related Quality of life (EQ-5D Index) 
 
 
R2  Beta   t  95% Confidence intervals   sig 
     lower  upper 
 
   0.26   
 
MDS-UPDRS-III   -0.003   -8.4  -0.004  -0.003    <0.001  
  
MDS-UPDRS-IV   -0.016   -7.1  -0.021  -0.012    <0.001 
 
SFMPQ    -0.014   -16.6  -0.015  -0.012    <0.001 
_____________________________________________________________________________________________ 
 
 
MDS-UPDRS-III, Unified Parkinson’s disease Rating Scale Part III (motor examination); MDS-UPDRS-IV, Unified Parkinson’s 
disease Rating Scale Part IV (motor complications); SFMPQ, Short Form McGill Pain Questionnaire.  
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Table 3: Multiple linear regression for pain severity - Short form McGill Pain Questionnaire 
(SFMPQ) 
 
 
R2  Beta    t  95% Confidence intervals  sig 
     lower   upper 
 
   0.21   
 
MDS-UPDRS-III   0.003   0.185  -0.031   0.038   0.853   
MDS-UPDRS-IV   0.213   2.121  0.016   0.411   0.034 
SCOPA    0.224   6.031  0.151   0.297   <0.001 
LADS     0.224   5.347  0.142   0.307   <0.001 
MoCA     -0.005   -0.076  -0.135   0.125   0.940 
Age     -0.072   -2.801  -0.123   -0.022   0.005 
Disease Duration   0.071   0.676  -0.136   0.278   0.394  
Gender (Female)   1.619   3.450  0.698   2.540   0.001  
_____________________________________________________________________________________________ 
 
 
 
MDS-UPDRS-III, Unified Parkinson’s disease Rating Scale Part III (motor examination); MDS-UPDRS-IV, Unified Parkinson’s 
disease Rating Scale Part IV (motor complications); SCOPA-AUT, the Scales for Outcomes in Parkinson’s disease – Autonomic 
Symptoms; LADS, Leeds Anxiety and Depression Scale; MoCA, Montreal Cognitive Assessment.  
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Table 4: Correlation between the severity of individual subtypes of pain and other disease 
related symptoms. 
 
 Musculoskeletal Radicular OFF dystonic General OFF Dyskinetic Lower Abdo Visceral 
 
MDS-UPDRS-
III 
 
0.03 0.05 0.02 0.05*  -0.01 0.04 0.05*  
MDS-UPDRS-
III  (OFF) 
 
0.04 0.08 0.11* 0.06 0.06 0.09* 0.07 
UPDRS-IV 0.11**  0.12**  0.27**  0.20**  0.15**  0.05* 0.05* 
 
LADS-A 0.2**  0.22**  0.17**  0.19**  0.17**  0.14**  0.13**  
 
LADS-D 0.16**  0.18**  0.16**  0.17**  0.11**  0.14**  0.12**  
 
SCOPA-AUT 0.17**  0.14**  0.13**  0.17**  0.12* 0.19**  0.24**  
 
Constipation 0.10**  0.06* 0.05* 0.09**  0.04 0.17**  0.16**  
____________________________________________________________________________________________________ 
 
Spearman’s rank correlation coefficient (rho); * P<0.05; ** P<0.001 
Individual pain subtypes were quantified using the King’s Parkinson’s Pain Scale. 
 
MDS-UPDRS-III, Unified Parkinson’s disease Rating Scale Part III (motor examination); MDS-UPDRS-III (OFF), UPDRS-III after 12 
hours medication withdrawal; MDS-UPDRS-IV, Unified Parkinson’s disease Rating Scale Part IV (motor complications); SCOPA-
AUT, the Scales for Outcomes in Parkinson’s disease – Autonomic Symptoms; LADS-A, Leeds Anxiety and Depression Scale-
Anxiety; LADS-D, Leeds Anxiety and Depression Scale-Depression; Constipation, UPDRS 1.11. 
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early/moderate Parkinson’s disease 
 
 
Highlights 
 
 
• Pain is common in early/moderate PD and impairs quality of life more than 
motor symptoms 
• No correlation between mobility problems and musculoskeletal or radicular 
pain in early/moderate PD 
• No correlation between OFF motor symptoms and OFF period pain in 
early/moderate PD 
• Features of central pain sensitisation are common in early/moderate PD 
• Central factors are a more important cause of pain in early/moderate PD than 
previously considered 
 
 
 
 
